I wonder if we can develop suitable theranostics for gliomas. For example, we have identified SSTR2-targeted therapies in meningiomas. PSMA plays a role in angiogenesis in glial neoplasms, but it is not sufficient as a target yet.
However, there are many more targetable receptors. We will find them over time, and we are finding them..
Also important topics:
- How is Perillyl alcohol (POH) effective in glioblastoma and high-grade gliomas treatments? Our review article on this topic is attached
- We need to shed more light on the role of proton therapy in glioblastoma with more cases; this will happen over time because proton therapy is now becoming more widespread in many institutions.
- When it comes to immunotherapy... my perspective is this: even though glioblastomas are cold tumors with low TMB, this does not mean that they are not suitable for immunotherapy, even if they do not respond to well-known agents such as nivolumab and pembrolizumab. For me, the terms immunotherapy and immune therapy are different. We should look at it from this angle: the cGAS-STING pathway. I believe we should approach the treatment of glioblastomas through interleukins and interferons; but in doing so, we must also understand that we will not see sufficient effect when using cytotoxic agents. Even outside of CNS malignancies, I cannot understand the logic behind oncologists combining chemotherapy with immunotherapy in various cancers. Chemotherapy will indirectly kill the effectiveness of immunotherapy.
- We will see the results of PCNA-targeted therapies in HGGs in the future.
- Alteration of COL-A receptors may support a poor prognosis in glial neoplasms.
Kind regards and Sincerely,
------------------------------
Emirhan Harbi
Department of Molecular Biology and Genetics
Bahcesehir University
Istanbul
------------------------------
Original Message:
Sent: 08-18-2025 12:25
From: Ashley Aaroe
Subject: What excites you most about the future of neuro-oncology?
Immunotherapy? Targeted therapy? New diagnostics or surgical/radonc techniques? Advances in neuropathology or neuropsychology?
------------------------------
Ashley Aaroe
Neuro-Oncology Fellow
MD Anderson Cancer Center
Houston TX
------------------------------